Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictive value of serum adalimumab concentration for clinical response in rheumatoid arthritis
2010-021449-28Phase 4Active
- Sponsor
- CHRU Tours
- Start
- Aug 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of adalimumab in rheumatoid arthritis (RA), sponsored by CHRU Tours. Primary endpoints: Primary concentration–response characterization and Target adalimumab concentration at 26 weeks. Started Aug 2010; status: active.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-021449-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021449-28.